| The New York Times 2004 Andrew Pollack |
| Title | Subject | Authors |
|---|
| 2 Engines of Biotech on a Collision Course.(Business/Financial Desk)(TECHNOLOGY) | News, opinion and commentary | Andrew Pollack |
| A New Trial of Celebrex, and Questions on Its Timing.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Californians to Vote on Spending $3 Billion on Stem Cell Research.(National Desk) | News, opinion and commentary | Andrew Pollack, John M. Broder |
| Eyetech Pins Its Hopes (And Shares) On New Drug.(Business/Financial Desk)(MARKET PLACE) | News, opinion and commentary | Andrew Pollack |
| Genes From Engineered Grass Spread for Miles, Study Finds.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Icahn Offers $5.4 Billion For Mylan, Drug Maker.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| In Drug Research, Some Guinea Pigs Are Now Human.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Justice Dept. And S.E.C. Investigating Merck Drug.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| New Scrutiny of Drugs in Vioxx's Family.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Panel to Review Drug for Low Female Sex Drive.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Sometimes, Vaccines Can Be Good for Business.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| Studies Find Biotechnology Anemia Drug Shows Promise in Treating Several Diseases.(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
| With New Sleeping Pill, New Acceptability?(Business/Financial Desk) | News, opinion and commentary | Andrew Pollack |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
